



## DECEMBER REPORT

### A CLOSER LOOK AT EPILEPSY AND SEIZURE DISORDERS

*"Introducing RYAH Data, our new data analytics report leveraging insights from our proprietary data lake."  
- Gregory Wagner,  
CEO, Ryah Medtech, Inc.*

## THE QUESTION

What do we know about flower for seizure disorders and epilepsy, as reported by patients within the RYAH Data ecosystem?

#### FOR MORE INFORMATION CONTACT

 205 East 42nd Street 14th floor  
New York 10017

 +1 917.210.0543

 [info@ryah.com](mailto:info@ryah.com)

 <https://ryah.com>  
<https://ryahgroup.com/>

## THE ANSWER

**2,894 patients with a seizure disorder reported through RYAH Data between Jan 1, 2018, and Nov 28, 2019.**

Patients overwhelmingly prefer CBD-rich strains for the alleviation of symptoms as well as general use. Pure OG and Super Lemon Haze are the exceptions, with medium-high levels of THC.

Slightly more men than women rely on the plant for epilepsy and other seizure disorders. Most reports in RYAH Data are from patients under the age of 30.

## STRAIN SNAP SHOT

**75** PERCENT OF TOP  
RATED STRAINS  
ARE CBD-RICH


This report is based on information pulled from RYAH Data between January 1, 2018, and November 28, 2019, filtering for Dravet Syndrome, epilepsy, seizures, and status epilepticus.

## ADDITIONAL DATA


The Food and Drugs Administration approved the first cannabis-derived pharmaceutical, Epidiolex®, in June 2018. It is primarily cannabidiol (CBD).

According to prescribing notes, "EPIDIOLEX is indicated for the treatment of seizures associated with Lennox-Gastaut syndrome or Dravet syndrome in patients 2 years of age and older." (1)


## GENDER



## AGE



## AILMENT TREATED



# ADDITIONAL DATA


A systematic review and meta-analysis publishing in a 2020 issue of Epilepsy & Behavior reported tolerable side effect profiles from studies with pure CBD and with extracts containing low-levels of THC. (3)

The authors indicated weight loss as related to appetite suppression was the most common adverse event.


Patients in RYAH Data reported appetite suppression as a common side effect for many of the CBD-rich top rated strains for seizure disorders.

# PREFERENCES


## TYPE



## STRAIN PREFERENCE OVERALL



## STRAIN PREFERENCE FOR CHANGE IN SYMPTOMS



## ADDITIONAL SOURCES

(1)

**"HIGHLIGHTS OF PRESCRIBING INFORMATION."** Access Data, Food and Drug Administration, June 2018, [www.accessdata.fda.gov/drugsatfda\\_docs/label/2018/2103651bl.pdf](http://www.accessdata.fda.gov/drugsatfda_docs/label/2018/2103651bl.pdf).

(2)

**"Find Marijuana Dispensary, Strain & Doctor Info & Ratings."** AllBud, [www.allbud.com/](http://www.allbud.com/). All strain information including type (sativa, indica, hybrid) and cannabinoid break down should be used as generalizations only.

(3)

Reis, Renandro De Carvalho, et al. **"Efficacy and Adverse Event Profile of Cannabidiol and Medicinal Cannabis for Treatment-Resistant Epilepsy: Systematic Review and Meta-Analysis."** *Epilepsy & Behavior*, vol. 102, 2020, p. 106635., doi:10.1016/j.yebeh.2019.106635.

### FOR MORE INFORMATION CONTACT



205 East 42nd Street 14th floor  
New York 10017



+1 917.210.0543



[info@ryah.com](mailto:info@ryah.com)



<https://ryah.com>